Two National Guard members shot near White House
Investing.com -- A sweeping new coverage report on U.S. health-care technology and services identifies five stocks as the analysts’ highest-conviction ideas, citing company-specific catalysts that align with broader transformations in how care is delivered, paid for and developed.
Phreesia is highlighted for renewed revenue momentum and tighter spending discipline. The report notes that average revenue per client, which had been “~flattish for nearly three years,” began rising in late 2024 and continued accelerating each quarter, lifted by stronger Network Solutions traction and cross-selling of add-ons such as VoiceAI and AccessOne.
Operating expenses have fallen to “~$75M/qtr, down from ~$80M/qtr,” a level management believes can be sustained. Analysts initiate the stock at "outperform" with a $32 target, valued at 16x 2026 EBITDA.
LifeStance is cited for its shift toward improving clinician productivity and the impact of several operational initiatives.
The brokerage says clinician schedules are currently “only 70-80% utilized,” with management aiming to move them closer to 90%. Recent steps include enhanced patient-provider matching tools, a new digital check-in system and adjustments to scheduling rules.
These moves accompanied an acceleration in revenue growth to 16% in the third quarter from roughly 11% in the second.
The stock is initiated at "outperform" with an $8 target based on what analysts call a disconnect between its ~16x 2026 EBITDA valuation and its projected two-year 20%+ EBITDA CAGR.
Privia is presented as a long-term earnings compounder with substantial expansion potential. The report notes the company’s 5,250+ implemented providers across 15 states and Washington, D.C., and highlights its physician-enablement model designed to improve practice operations and support participation in value-based care programs.
Privia manages 1.4 million attributed lives across more than 100 value-based care contracts, operating with what analysts describe as a more disciplined approach to risk that requires shared incentives across payers and providers.
The analysts initiate at "outperform" with a $30 target, citing expectations for 20%+ EBITDA growth and sustained 80%+ free cash flow conversion.
IQVIA is described as emerging from a prolonged period of pharma R&D reprioritization that had weighed on earnings and sentiment. The firm holds “61+ petabytes and 1.2B+ unique patient records” and has invested heavily in AI tools that now support many aspects of drug development and commercialization.
Proprietary data analysis in the report suggests that the worst of cancellation-related headwinds “are now behind it,” setting up a re-acceleration in EPS and valuation into 2026.
Although shares have risen 55% since April lows, analysts note the stock continues to trade eight turns below the S&P 500’s valuation. IQVIA is initiated at "outperform" with a $260 target.
BrightSpring is highlighted for strong specialty-pharmacy momentum and its position to benefit from additional limited-distribution drug wins and generic conversions. The report notes the stock is up 97% year-to-date, driven largely by LDD gains.
BrightSpring combines pharmacy operations with home- and community-based services for high-need and complex patients, a model analysts say provides long-range integration opportunities.
The brokerage projects 12%+ EBITDA growth over the next three-plus years, supported by oncology LDD traction, census gains in home health, integration improvements, automation and AI initiatives, and continued M&A activity, excluding unannounced deals. Analysts initiate the stock at "outperform" with a $40 target.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.